November 1, 2013
Bookmark and Share  
 
                 
  HCV
»
»
»
»
»



Follow us on
Twitter

HCVAdvocate


Join us on Facebook
Hcvadvocate Hcsp

.

.

 

Hello:

Happy Halloween! We hope that you have a good trick or treat, but remember living well with hepatitis C is all about moderation. This month we have a jam-packed November HCV Advocate newsletter, updated fact sheets, and we will be providing extensive coverage of the upcoming American Association for the Study of Liver Diseases Conference

Enjoy,

Alan

 

1. HCV Advocate Newsletter: November, 2013

In This Issue:

  • Game Changers: AbbVie and Gilead
    Alan Franciscus, Editor-in-Chief
    The first interferon-free therapies to treat chronic hepatitis C genotype 1 patients are currently completing studies and approval is expected in 2014. In this issue, I discuss the drugs that are most likely to be the first interferon-free therapies that will be approved by the Food and Drug Administration.

  • Snapshots
    Lucinda K. Porter, RN
    This month Lucinda summarizes various studies:
    • The number of deaths from hepatitis C – This is an eye-opening study which will reshape our understanding of deaths caused by hepatitis C. 
    • Liver stiffness and how it relates to hepatitis C infection vs. HIV infection.
    • Prisons and HCV – and an estimate of the number of people with HCV in prisons worldwide.
    • What does a cure translate to for HCV disease progression in people who are HIV/HCV coinfected?

  • HEALTHWISE: Military Veterans and Hepatitis C)
    Lucinda K. Porter, RN

    In this month's column, Lucinda writes about hepatitis C and veterans with a discussion about the personal impact of HCV on veterans. In many ways, the Armed Services and veterans in this country have not been provided the care and support needed especially when one considers that many have scarified their lives for our country. We should all be advocating for those people who serve or have served our country and especially for the veterans who are infected with hepatitis C.

  • Prescription Drugs – Off-label Use
    Alan Franciscus, Editor-in-Chief
    You may (or may not) be surprised by the amount of medications that are prescribed as off-label. This is particularly important to people with hepatitis C as new drugs are approved by the Food and Drug Administration (FDA) that a medical provider could prescribe. I discuss why off-label use is important for everyone, why it may be even more important for people with HCV and the potential benefits and risks of prescribing (and taking) medications that have not been well-studied to treat certain conditions, or in the case of HCV, combinations of drugs that may not have been adequately studied in combination.

  • Flu-Shots
    Lucinda K. Porter, RN

    This articles reminds us all that we need to get the flu-shot to protect ourselves from getting the flu and from the potentially serious complications of the flu. The article also discusses the six different vaccines to protect against getting the flu. Personally, I got the flu about 10 years ago and it was one of the most miserable times of my life. Since that hard-learned lesson I have had an annual flu shot and I have never had the flu again.

 

2. HBV Journal Review by Christine Kukka —In this month's column Chris reviews the following studies that will help you understand the complexities of hepatitis B:

  • Patients Who Clear Hepatitis B During Antiviral Treatment Do Well Long-Term
  • However, the Prognosis is Poor for Most Who Stop Antiviral Treatment
  • How Effective Are Antivirals in Reducing Cirrhosis and Preventing Liver Cancer?
  • New Antiviral Besifovir Hampered by Carnitine Deficiency in Early Clinical Trial
  • Liver Cancer Remains Major Health Threat, with Few Treatment Options
  • Scientists Develop a Better Mouse for Hepatitis B and C Research
  • HBV-Infected People Have a Higher Risk of Rheumatoid Arthritis
  • Ear Wax May Transmit Hepatitis B
  • Children with Frequent Ear Infections Do Not Respond as Well to Vaccines
  • Clean-Shave Haircuts Leave Traces of Virus on the Scalp

 

3. Interview with Lucinda Porter, RN, author of newly released Hepatitis C Treatment One Step at a Time and Free from Hepatitis C

One Step at a Time

Click Here

 

4. A Guide to the Affordable Care Act (ACA); Updated!—By Jacques Chambers, CLU
We have compiled Jacques' articles on the ACA to help our readers better understand this confusing and complex new law. Click Here.

 

5. New & Updated Fact Sheets and Guides
We have added new fact sheets and updated many of our HCV fact sheets.

HCV Drugs in Development
PDF Genotype 2 and 3 –The latest Information on the next standard of care for people with HCV Genotype 2 and for some with genotype 3.
PDF Phase 3 Genotype 1 — DAA plus PEG/RBV – This fact sheet updates and summarizes the next standard of care for treating HCV genotype 1.

Other series that have been updated are:

  • Being an Effective Healthcare Consumer
  • HCV Education and Support
  • HCV and Mental Health
  • HCV Treatment – Side Effect Management
  • HCV Wellness

Click Here to see all.

 

6. Clinical Trials Postings: Updated—October 15, 2013!
Be sure to check out the latest clinical trial postings at the HCV Advocate News & Pipeline Blog. Just click on the links to the Drug Companies below the banner to see which drugs are in trials right now, where the trials are, and how to register for one.

-----------------------------------

 

Don’t forget that there is help as close as a phone call – the 877-HELP-4-HEP line (877-435-7443) is available 9:00am to 7:00pm Eastern Time.  For more information about the services they offer either call or visit their Website at www.help4hep.org  The helpline is run by The Support Partnership:  a group of non-profits working together to help people affected by hepatitis C. 

 

7. Top News (Blog) from the HCV Advocate News & Pipeline Blog includes: 

Top News

New REP 9AC Clinical Trial, Adding Interferon and Antivirals, Begins in Europe, with comments by Christine. M. Kukka, Project Manager, HBV Advocate
Oct 30

FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab), with comments by Alan Franciscus
Oct 29

FDA Hepatitis Update - Changes to Incivek (telaprevir) product labeling
Oct 29

Is the genotype 3 of the hepatitis C virus the new villain? with comments by Alan Franciscus
Oct 29

Seronegative hepatitis C virus infection in patients with lymphoproliferative disorders, with comments by Alan Franciscus
Oct 29

 

 

and much, much more…..

———————————————

 

 

Sincerely,

Alan

 

Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org

 

**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org

**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.

 
  HBV
»
»
»



Follow us on Twitter
HBVAdvocate